Baird Maintains Outperform on Medline, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 93.8%

Neg 93.8% Neu 0% Pos 0%

Baird analyst Eric Coldwell maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $57 to $45.